# Leverett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 11 | 10.6 | 103.5 | (51.6-185.2) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 4 | 10.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 1.6 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 2 | 0.7 | nc | (nc-nc) |  | Female | 3 | 1.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 3 | 2.6 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 5.5 | 90.7 | (29.2-211.8) |  | Male | 24 | 38.8 | 61.9 | (39.6-92.1) |
| Female | 3 | 5.2 | nc | (nc-nc) |  | Female | 34 | 34.5 | 98.5 | (68.2-137.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

163

# Lexington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 25 | 40.7 | 61.4 | (39.8-90.7) |  | Male | 28 | 25.1 | 111.5 | (74.1-161.2) |
| Female | 5 | 15.6 | 32.1 | (10.3-74.9) |  | Female | 22 | 19.5 | 112.9 | (70.7-170.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 7.3 | 82.0 | (30.0-178.6) |  | Male | 11 | 8.2 | 133.6 | (66.6-239.1) |
| Female | 4 | 6.3 | nc | (nc-nc) |  | Female | 8 | 7.0 | 114.8 | (49.4-226.1) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 1.4 | nc | (nc-nc) |  | Male | 18 | 22.5 | 79.9 | (47.3-126.3) |
| Female | 175 | 162.0 | 108.0 | (92.6-125.3) |  | Female | 24 | 21.1 | 113.7 | (72.9-169.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 17 | 18.6 | 91.2 | (53.1-146.0) |
| Female | 1 | 4.9 | nc | (nc-nc) |  | Female | 7 | 8.8 | 79.5 | (31.8-163.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 38 | 43.1 | 88.2 | (62.4-121.1) |  |  |  |  |  |  |
| Female | 32 | 45.3 | 70.6 | (48.3-99.7) |  | Female | 15 | 14.0 | 107.3 | (60.0-176.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 10.3 | nc | (nc-nc) |  | Male | 10 | 14.4 | 69.6 | (33.3-128.1) |
| Female | 0 | 3.0 | nc | (nc-nc) |  | Female | 17 | 15.9 | 106.8 | (62.2-171.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  | Male | 131 | 124.0 | 105.6 | (88.3-125.3) |
| Female | 1 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 17 | 21.9 | 77.8 | (45.3-124.6) |  | Male | 3 | 9.7 | nc | (nc-nc) |
| Female | 4 | 13.1 | nc | (nc-nc) |  | Female | 6 | 6.2 | 97.3 | (35.5-211.9) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 6.0 | nc | (nc-nc) |  | Male | 4 | 3.8 | nc | (nc-nc) |
| Female | 0 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 14 | 16.0 | 87.2 | (47.7-146.4) |  | Male | 8 | 9.3 | 86.0 | (37.0-169.4) |
| Female | 12 | 12.1 | 99.2 | (51.2-173.3) |  | Female | 36 | 26.3 | 136.9 | (95.9-189.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 13.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 5 | 5.0 | 100.9 | (32.5-235.5) |  | Female | 29 | 36.0 | 80.7 | (54.0-115.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 28 | 71.8 | 39.0 | (25.9-56.4) |  | Male | 405 | 512.1 | 79.1 | (71.6-87.2) |
| Female | 45 | 80.2 | 56.1 | (40.9-75.1) |  | Female | 490 | 552.5 | 88.7 | (81.0-96.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

164

# Leyden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 3.9 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.1 | nc | (nc-nc) |  | Male | 2 | 3.2 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 10 | 11.8 | 84.7 | (40.5-155.7) |
| Female | 2 | 1.5 | nc | (nc-nc) |  | Female | 13 | 11.9 | 109.0 | (58.0-186.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

165

# Lincoln

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 9.4 | nc | (nc-nc) |  | Male | 7 | 5.5 | 127.7 | (51.2-263.1) |
| Female | 8 | 2.6 | 306.1 | (131.8-603.2) |  | Female | 8 | 3.6 | 222.5 | (95.8-438.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 1.6 | 318.9 | (102.8-744.3) |  | Male | 3 | 1.8 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 4 | 4.9 | nc | (nc-nc) |
| Female | 47 | 29.1 | 161.8 | (118.9-215.1) |  | Female | 4 | 3.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 3.7 | 136.7 | (44.0-319.0) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 9.5 | 73.5 | (29.5-151.5) |  |  |  |  |  |  |
| Female | 5 | 7.8 | 64.3 | (20.7-150.2) |  | Female | 4 | 2.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.1 | nc | (nc-nc) |  | Male | 5 | 3.2 | 157.8 | (50.8-368.2) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 2.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 43 | 23.5 | 183.2 | (132.6-246.8) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 4.4 | nc | (nc-nc) |  | Male | 0 | 2.2 | nc | (nc-nc) |
| Female | 3 | 2.3 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 2 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 3.6 | 165.7 | (60.5-360.6) |  | Male | 4 | 1.9 | nc | (nc-nc) |
| Female | 7 | 2.3 | 309.0 | (123.8-636.7) |  | Female | 4 | 5.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 11 | 6.5 | 168.3 | (83.9-301.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 15.6 | 44.7 | (17.9-92.2) |  | Male | 121 | 108.4 | 111.6 | (92.6-133.3) |
| Female | 9 | 13.5 | 66.6 | (30.4-126.5) |  | Female | 126 | 98.0 | 128.5 | (107.1-153.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

166

# Littleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 8.0 | 174.0 | (95.0-291.9) |  | Male | 6 | 5.7 | 104.7 | (38.2-227.8) |
| Female | 1 | 3.6 | nc | (nc-nc) |  | Female | 4 | 5.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 10 | 5.1 | 195.4 | (93.5-359.3) |
| Female | 42 | 42.4 | 99.0 | (71.3-133.8) |  | Female | 4 | 5.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 4.6 | 130.2 | (47.5-283.4) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 0 | 2.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 9.6 | 52.3 | (16.9-122.2) |  |  |  |  |  |  |
| Female | 7 | 10.8 | 64.8 | (26.0-133.5) |  | Female | 6 | 3.6 | 165.0 | (60.3-359.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.3 | nc | (nc-nc) |  | Male | 6 | 3.1 | 192.1 | (70.1-418.1) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 3 | 3.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 33 | 28.7 | 114.9 | (79.1-161.4) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 5.3 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 3 | 3.3 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 9 | 7.7 | 117.5 | (53.6-223.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 3.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 14 | 9.5 | 148.0 | (80.8-248.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 15.1 | 132.8 | (81.1-205.0) |  | Male | 130 | 115.3 | 112.8 | (94.2-133.9) |
| Female | 14 | 19.4 | 72.2 | (39.5-121.2) |  | Female | 122 | 139.8 | 87.3 | (72.5-104.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

167

# Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 22.3 | 67.1 | (37.5-110.7) |  | Male | 18 | 13.2 | 136.9 | (81.1-216.3) |
| Female | 7 | 8.2 | 85.6 | (34.3-176.3) |  | Female | 14 | 10.0 | 140.6 | (76.8-236.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 3.6 | nc | (nc-nc) |  | Male | 2 | 4.3 | nc | (nc-nc) |
| Female | 4 | 3.2 | nc | (nc-nc) |  | Female | 1 | 3.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 10 | 11.9 | 84.3 | (40.3-155.0) |
| Female | 86 | 80.2 | 107.2 | (85.8-132.4) |  | Female | 12 | 10.9 | 110.6 | (57.1-193.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 9.4 | 53.3 | (17.2-124.4) |
| Female | 0 | 2.4 | nc | (nc-nc) |  | Female | 0 | 4.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 23.2 | 47.5 | (23.7-85.0) |  |  |  |  |  |  |
| Female | 15 | 24.3 | 61.7 | (34.5-101.7) |  | Female | 5 | 7.1 | 70.6 | (22.7-164.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 5.3 | nc | (nc-nc) |  | Male | 3 | 7.7 | nc | (nc-nc) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 4 | 8.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 54 | 63.1 | 85.6 | (64.3-111.7) |
| Female | 2 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 11.0 | 99.9 | (49.8-178.9) |  | Male | 5 | 5.2 | 96.1 | (31.0-224.3) |
| Female | 3 | 6.6 | nc | (nc-nc) |  | Female | 2 | 3.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 3.0 | nc | (nc-nc) |  | Male | 3 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 15 | 8.4 | 178.3 | (99.7-294.0) |  | Male | 5 | 4.5 | 111.5 | (35.9-260.2) |
| Female | 2 | 6.4 | nc | (nc-nc) |  | Female | 9 | 12.9 | 69.9 | (31.9-132.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 7.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 6 | 2.5 | 238.0 | (86.9-518.0) |  | Female | 12 | 17.7 | 67.8 | (35.0-118.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 24 | 38.2 | 62.9 | (40.3-93.6) |  | Male | 213 | 267.6 | 79.6 | (69.3-91.0) |
| Female | 24 | 40.5 | 59.3 | (38.0-88.3) |  | Female | 234 | 281.3 | 83.2 | (72.9-94.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

168

# Lowell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 75 | 81.8 | 91.7 | (72.1-114.9) |  | Male | 32 | 56.9 | 56.2 | (38.5-79.4) |
| Female | 37 | 31.9 | 115.9 | (81.6-159.7) |  | Female | 26 | 49.1 | 53.0 | (34.6-77.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 15 | 19.8 | 75.9 | (42.5-125.2) |  | Male | 17 | 17.5 | 97.1 | (56.5-155.4) |
| Female | 14 | 16.1 | 87.0 | (47.5-146.0) |  | Female | 23 | 14.7 | 156.5 | (99.2-234.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  | Male | 44 | 51.3 | 85.8 | (62.3-115.2) |
| Female | 307 | 371.9 | 82.5 | (73.6-92.3) |  | Female | 36 | 46.5 | 77.4 | (54.2-107.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 58 | 44.1 | 131.5 | (99.9-170.0) |
| Female | 17 | 14.0 | 121.2 | (70.6-194.1) |  | Female | 13 | 19.6 | 66.4 | (35.3-113.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 87 | 94.7 | 91.9 | (73.6-113.4) |  |  |  |  |  |  |
| Female | 101 | 96.5 | 104.7 | (85.3-127.2) |  | Female | 25 | 32.3 | 77.4 | (50.1-114.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 22 | 22.2 | 99.0 | (62.0-150.0) |  | Male | 29 | 30.5 | 95.2 | (63.8-136.8) |
| Female | 4 | 6.2 | nc | (nc-nc) |  | Female | 28 | 32.5 | 86.2 | (57.2-124.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 14 | 9.3 | 149.8 | (81.8-251.4) |  | Male | 214 | 277.2 | 77.2 | (67.2-88.3) |
| Female | 4 | 7.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 59 | 51.1 | 115.6 | (88.0-149.1) |  | Male | 25 | 20.6 | 121.2 | (78.4-178.9) |
| Female | 34 | 29.4 | 115.7 | (80.1-161.7) |  | Female | 32 | 13.1 | 244.5 | (167.2-345.2) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 16 | 13.1 | 122.2 | (69.8-198.5) |  | Male | 14 | 18.6 | 75.4 | (41.2-126.6) |
| Female | 6 | 4.0 | 151.1 | (55.2-329.0) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 35 | 37.3 | 94.0 | (65.4-130.7) |  | Male | 17 | 26.2 | 64.9 | (37.8-104.0) |
| Female | 35 | 28.4 | 123.4 | (85.9-171.6) |  | Female | 79 | 80.0 | 98.7 | (78.1-123.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 65 | 31.6 | 205.9 | (158.9-262.4) |  |  |  |  |  |  |
| Female | 7 | 10.7 | 65.5 | (26.2-135.0) |  | Female | 81 | 81.2 | 99.7 | (79.2-124.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 178 | 147.7 | 120.5 | (103.4-139.6) |  | Male | 1135 | 1145.1 | 99.1 | (93.4-105.1) |
| Female | 191 | 166.5 | 114.7 | (99.0-132.2) |  | Female | 1200 | 1252.9 | 95.8 | (90.4-101.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

169

# Ludlow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 28 | 25.4 | 110.2 | (73.2-159.3) |  | Male | 12 | 16.3 | 73.7 | (38.0-128.7) |
| Female | 4 | 10.2 | nc | (nc-nc) |  | Female | 15 | 13.1 | 114.1 | (63.8-188.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 4.8 | nc | (nc-nc) |  | Male | 3 | 5.2 | nc | (nc-nc) |
| Female | 2 | 4.2 | nc | (nc-nc) |  | Female | 5 | 4.6 | 108.4 | (34.9-253.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 14 | 14.5 | 96.7 | (52.8-162.2) |
| Female | 88 | 108.1 | 81.4 | (65.3-100.3) |  | Female | 13 | 14.0 | 92.8 | (49.4-158.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 12.5 | 56.0 | (22.4-115.5) |
| Female | 7 | 3.3 | 209.7 | (84.0-432.1) |  | Female | 4 | 5.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 29 | 27.6 | 104.9 | (70.3-150.7) |  |  |  |  |  |  |
| Female | 27 | 29.5 | 91.5 | (60.3-133.1) |  | Female | 9 | 9.3 | 96.5 | (44.0-183.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 6.7 | nc | (nc-nc) |  | Male | 8 | 9.2 | 87.3 | (37.6-172.0) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 12 | 10.4 | 114.9 | (59.3-200.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 67 | 83.1 | 80.6 | (62.5-102.4) |
| Female | 1 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 23 | 14.4 | 159.5 | (101.1-239.4) |  | Male | 8 | 6.2 | 129.8 | (55.9-255.8) |
| Female | 5 | 8.7 | 57.6 | (18.6-134.4) |  | Female | 4 | 4.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 3.9 | nc | (nc-nc) |  | Male | 1 | 3.1 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 10.1 | 69.1 | (27.7-142.4) |  | Male | 4 | 6.4 | nc | (nc-nc) |
| Female | 6 | 8.0 | 75.3 | (27.5-163.8) |  | Female | 6 | 18.0 | 33.3 | (12.2-72.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 9.3 | 75.6 | (30.3-155.8) |  |  |  |  |  |  |
| Female | 2 | 3.3 | nc | (nc-nc) |  | Female | 22 | 24.4 | 90.3 | (56.6-136.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 32 | 45.6 | 70.2 | (48.0-99.1) |  | Male | 292 | 333.2 | 87.6 | (77.9-98.3) |
| Female | 34 | 53.2 | 63.9 | (44.2-89.2) |  | Female | 299 | 367.4 | 81.4 | (72.4-91.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

170

# Lunenburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 12.7 | 70.8 | (32.3-134.3) |  | Male | 8 | 8.0 | 99.6 | (42.9-196.3) |
| Female | 6 | 4.2 | 142.3 | (52.0-309.8) |  | Female | 3 | 6.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 2.4 | nc | (nc-nc) |  | Male | 4 | 2.6 | nc | (nc-nc) |
| Female | 3 | 2.0 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 5 | 7.3 | 69.0 | (22.2-160.9) |
| Female | 55 | 50.8 | 108.2 | (81.5-140.8) |  | Female | 6 | 6.2 | 97.5 | (35.6-212.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 6.1 | 147.0 | (67.1-279.2) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 0 | 2.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 14 | 14.0 | 99.7 | (54.5-167.3) |  |  |  |  |  |  |
| Female | 14 | 12.5 | 112.1 | (61.2-188.1) |  | Female | 3 | 4.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 3.3 | nc | (nc-nc) |  | Male | 4 | 4.5 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 2 | 4.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 0.9 | nc | (nc-nc) |  | Male | 42 | 40.1 | 104.8 | (75.5-141.7) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 7.2 | 97.7 | (39.1-201.3) |  | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 3 | 3.9 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 1.9 | nc | (nc-nc) |  | Male | 3 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 5.1 | 157.9 | (68.0-311.1) |  | Male | 4 | 3.2 | nc | (nc-nc) |
| Female | 4 | 3.4 | nc | (nc-nc) |  | Female | 10 | 9.0 | 110.6 | (52.9-203.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 4.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 1.5 | nc | (nc-nc) |  | Female | 15 | 11.9 | 126.2 | (70.6-208.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 24 | 22.4 | 107.0 | (68.6-159.3) |  | Male | 168 | 164.2 | 102.3 | (87.4-119.0) |
| Female | 16 | 22.7 | 70.5 | (40.3-114.5) |  | Female | 156 | 165.8 | 94.1 | (79.9-110.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

171

# Lynn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 72 | 71.3 | 101.0 | (79.1-127.3) |  | Male | 43 | 48.4 | 88.8 | (64.3-119.6) |
| Female | 25 | 28.7 | 87.1 | (56.4-128.7) |  | Female | 31 | 42.7 | 72.6 | (49.3-103.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 19 | 16.5 | 115.4 | (69.4-180.2) |  | Male | 32 | 15.2 | 211.1 | (144.4-298.0) |
| Female | 17 | 14.2 | 119.4 | (69.5-191.2) |  | Female | 16 | 13.1 | 121.7 | (69.5-197.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 5 | 2.6 | 194.2 | (62.6-453.2) |  | Male | 51 | 43.8 | 116.4 | (86.7-153.1) |
| Female | 325 | 328.7 | 98.9 | (88.4-110.2) |  | Female | 51 | 41.2 | 123.8 | (92.2-162.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 50 | 36.8 | 135.9 | (100.8-179.1) |
| Female | 16 | 12.0 | 133.8 | (76.4-217.2) |  | Female | 19 | 17.4 | 109.2 | (65.7-170.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 120 | 81.8 | 146.8 | (121.7-175.5) |  |  |  |  |  |  |
| Female | 111 | 85.6 | 129.6 | (106.6-156.1) |  | Female | 24 | 28.6 | 84.0 | (53.8-125.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 21 | 18.9 | 111.0 | (68.7-169.7) |  | Male | 27 | 26.1 | 103.6 | (68.3-150.8) |
| Female | 5 | 5.6 | 89.4 | (28.8-208.6) |  | Female | 24 | 29.2 | 82.2 | (52.7-122.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 7.4 | 67.4 | (21.7-157.2) |  | Male | 290 | 232.0 | 125.0 | (111.0-140.2) |
| Female | 2 | 6.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 35 | 43.1 | 81.2 | (56.5-112.9) |  | Male | 21 | 17.8 | 118.1 | (73.1-180.5) |
| Female | 28 | 26.2 | 106.9 | (71.0-154.6) |  | Female | 22 | 11.6 | 189.9 | (118.9-287.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 15 | 11.1 | 134.8 | (75.4-222.4) |  | Male | 14 | 14.6 | 96.1 | (52.5-161.3) |
| Female | 4 | 3.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 46 | 31.6 | 145.6 | (106.6-194.2) |  | Male | 20 | 21.7 | 92.2 | (56.3-142.4) |
| Female | 32 | 25.3 | 126.6 | (86.6-178.7) |  | Female | 53 | 68.3 | 77.6 | (58.2-101.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 57 | 26.3 | 216.5 | (164.0-280.6) |  |  |  |  |  |  |
| Female | 18 | 9.5 | 188.7 | (111.8-298.2) |  | Female | 73 | 72.3 | 101.0 | (79.2-127.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 195 | 127.2 | 153.3 | (132.5-176.4) |  | Male | 1230 | 972.1 | 126.5 | (119.6-133.8) |
| Female | 171 | 150.5 | 113.7 | (97.3-132.0) |  | Female | 1176 | 1110.3 | 105.9 | (99.9-112.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

172

# Lynnfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 15.7 | 76.2 | (39.3-133.1) |  | Male | 24 | 9.9 | 242.3 | (155.2-360.5) |
| Female | 10 | 5.4 | 184.8 | (88.5-339.8) |  | Female | 13 | 7.1 | 184.4 | (98.1-315.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  | Male | 5 | 3.2 | 154.8 | (49.9-361.4) |
| Female | 4 | 2.3 | nc | (nc-nc) |  | Female | 4 | 2.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 14 | 8.8 | 158.9 | (86.8-266.6) |
| Female | 60 | 58.7 | 102.2 | (78.0-131.6) |  | Female | 13 | 7.4 | 175.1 | (93.2-299.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 7.5 | 67.0 | (21.6-156.3) |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 13 | 17.0 | 76.6 | (40.7-130.9) |  |  |  |  |  |  |
| Female | 21 | 15.7 | 133.8 | (82.8-204.6) |  | Female | 8 | 5.0 | 158.6 | (68.3-312.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 4.1 | nc | (nc-nc) |  | Male | 5 | 5.6 | 89.4 | (28.8-208.5) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 7 | 5.5 | 127.3 | (51.0-262.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 44 | 49.7 | 88.6 | (64.4-118.9) |
| Female | 2 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 8.7 | 80.6 | (32.3-166.0) |  | Male | 2 | 3.8 | nc | (nc-nc) |
| Female | 4 | 4.7 | nc | (nc-nc) |  | Female | 3 | 2.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  | Male | 6 | 1.6 | 373.7 | (136.4-813.3) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 6.1 | 179.5 | (89.5-321.3) |  | Male | 6 | 3.8 | 159.3 | (58.2-346.7) |
| Female | 3 | 4.2 | nc | (nc-nc) |  | Female | 18 | 9.9 | 181.4 | (107.5-286.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 5.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 17 | 13.1 | 129.8 | (75.6-207.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 28.2 | 67.3 | (40.5-105.1) |  | Male | 190 | 202.0 | 94.1 | (81.2-108.4) |
| Female | 29 | 28.4 | 102.0 | (68.3-146.5) |  | Female | 233 | 197.4 | 118.0 | (103.4-134.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

173

# Malden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 27 | 46.7 | 57.8 | (38.1-84.1) |  | Male | 10 | 32.5 | 30.7 | (14.7-56.5) |
| Female | 21 | 18.9 | 111.4 | (68.9-170.3) |  | Female | 16 | 29.4 | 54.3 | (31.0-88.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 10.9 | 46.1 | (14.8-107.5) |  | Male | 7 | 10.1 | 69.1 | (27.7-142.4) |
| Female | 7 | 9.3 | 75.0 | (30.0-154.5) |  | Female | 5 | 8.7 | 57.3 | (18.4-133.6) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 1.7 | nc | (nc-nc) |  | Male | 43 | 29.2 | 147.2 | (106.5-198.3) |
| Female | 185 | 223.3 | 82.9 | (71.3-95.7) |  | Female | 26 | 27.6 | 94.3 | (61.6-138.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 23 | 24.7 | 93.2 | (59.1-139.9) |
| Female | 15 | 8.7 | 172.8 | (96.7-285.1) |  | Female | 11 | 11.6 | 94.7 | (47.2-169.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 71 | 53.4 | 132.9 | (103.8-167.6) |  |  |  |  |  |  |
| Female | 72 | 57.6 | 125.0 | (97.8-157.5) |  | Female | 16 | 19.2 | 83.4 | (47.6-135.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 17 | 12.6 | 134.9 | (78.6-216.1) |  | Male | 20 | 17.2 | 116.2 | (70.9-179.4) |
| Female | 8 | 3.6 | 219.8 | (94.6-433.1) |  | Female | 18 | 19.3 | 93.3 | (55.3-147.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 5.3 | nc | (nc-nc) |  | Male | 128 | 152.3 | 84.0 | (70.1-99.9) |
| Female | 4 | 4.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 36 | 28.9 | 124.8 | (87.4-172.7) |  | Male | 16 | 11.7 | 136.3 | (77.9-221.4) |
| Female | 21 | 17.4 | 120.9 | (74.8-184.8) |  | Female | 7 | 7.8 | 89.7 | (35.9-184.9) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 9 | 7.4 | 121.4 | (55.4-230.5) |  | Male | 7 | 10.8 | 65.0 | (26.0-133.9) |
| Female | 2 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 22 | 20.7 | 106.1 | (66.5-160.6) |  | Male | 15 | 15.1 | 99.4 | (55.6-163.9) |
| Female | 16 | 16.6 | 96.5 | (55.1-156.6) |  | Female | 59 | 49.1 | 120.3 | (91.5-155.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 25 | 17.7 | 141.5 | (91.6-208.9) |  |  |  |  |  |  |
| Female | 16 | 6.3 | 255.2 | (145.8-414.5) |  | Female | 50 | 48.0 | 104.2 | (77.3-137.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 116 | 83.9 | 138.3 | (114.3-165.9) |  | Male | 639 | 644.5 | 99.1 | (91.6-107.1) |
| Female | 108 | 97.9 | 110.3 | (90.5-133.2) |  | Female | 740 | 746.7 | 99.1 | (92.1-106.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

174

# Manchester by the Sea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 8.1 | nc | (nc-nc) |  | Male | 9 | 4.7 | 191.1 | (87.2-362.7) |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 5 | 3.4 | 146.6 | (47.2-342.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.3 | nc | (nc-nc) |  | Male | 8 | 4.2 | 188.5 | (81.2-371.4) |
| Female | 29 | 29.3 | 99.0 | (66.3-142.2) |  | Female | 2 | 3.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 3.4 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 8.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 6 | 7.6 | 79.4 | (29.0-172.7) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 2.0 | nc | (nc-nc) |  | Male | 0 | 2.8 | nc | (nc-nc) |
| Female | 3 | 0.5 | nc | (nc-nc) |  | Female | 4 | 2.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 24 | 23.3 | 102.9 | (65.9-153.1) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 4.0 | nc | (nc-nc) |  | Male | 0 | 1.9 | nc | (nc-nc) |
| Female | 0 | 2.3 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 3 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 3.0 | nc | (nc-nc) |  | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 8 | 4.6 | 174.3 | (75.1-343.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 6 | 6.7 | 89.1 | (32.5-193.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 8 | 13.7 | 58.3 | (25.1-114.9) |  | Male | 84 | 97.0 | 86.6 | (69.1-107.2) |
| Female | 8 | 14.6 | 55.0 | (23.7-108.3) |  | Female | 86 | 97.8 | 87.9 | (70.3-108.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

175

# Mansfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 24 | 16.7 | 143.3 | (91.8-213.2) |  | Male | 25 | 12.2 | 205.5 | (132.9-303.3) |
| Female | 0 | 5.8 | nc | (nc-nc) |  | Female | 21 | 10.3 | 203.9 | (126.2-311.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 4.2 | 189.3 | (81.5-373.0) |  | Male | 5 | 3.8 | 131.9 | (42.5-307.8) |
| Female | 6 | 3.4 | 178.9 | (65.3-389.3) |  | Female | 1 | 2.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.6 | nc | (nc-nc) |  | Male | 13 | 11.0 | 118.4 | (63.0-202.5) |
| Female | 93 | 83.6 | 111.3 | (89.8-136.3) |  | Female | 3 | 9.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 9.9 | 101.0 | (48.4-185.8) |
| Female | 1 | 3.2 | nc | (nc-nc) |  | Female | 1 | 4.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 25 | 20.6 | 121.3 | (78.4-179.0) |  |  |  |  |  |  |
| Female | 27 | 19.0 | 142.4 | (93.8-207.1) |  | Female | 8 | 7.0 | 114.7 | (49.4-226.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 4.8 | nc | (nc-nc) |  | Male | 5 | 6.4 | 77.8 | (25.1-181.5) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 6 | 5.9 | 101.3 | (37.0-220.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 60 | 59.3 | 101.1 | (77.2-130.2) |
| Female | 1 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 11.4 | 114.5 | (60.9-195.8) |  | Male | 5 | 4.4 | 114.7 | (37.0-267.8) |
| Female | 5 | 6.2 | 81.2 | (26.2-189.4) |  | Female | 4 | 2.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 2.8 | nc | (nc-nc) |  | Male | 8 | 3.5 | 231.6 | (99.7-456.4) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 7.8 | 76.6 | (28.0-166.8) |  | Male | 15 | 5.9 | 254.9 | (142.6-420.5) |
| Female | 11 | 5.4 | 202.7 | (101.0-362.6) |  | Female | 17 | 18.1 | 93.7 | (54.6-150.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 9 | 6.9 | 131.0 | (59.8-248.7) |  |  |  |  |  |  |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 11 | 18.0 | 61.2 | (30.5-109.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 35 | 30.6 | 114.5 | (79.7-159.2) |  | Male | 284 | 243.5 | 116.6 | (103.4-131.0) |
| Female | 34 | 31.7 | 107.4 | (74.4-150.1) |  | Female | 282 | 260.5 | 108.2 | (96.0-121.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

176

# Marblehead

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 23 | 27.4 | 83.8 | (53.1-125.8) |  | Male | 41 | 16.5 | 248.1 | (178.0-336.6) |
| Female | 10 | 9.7 | 103.2 | (49.4-189.7) |  | Female | 26 | 12.6 | 205.7 | (134.3-301.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 4.7 | nc | (nc-nc) |  | Male | 8 | 5.5 | 146.7 | (63.2-289.2) |
| Female | 3 | 4.1 | nc | (nc-nc) |  | Female | 7 | 4.4 | 158.3 | (63.4-326.1) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 14 | 14.9 | 94.1 | (51.4-157.9) |
| Female | 126 | 107.1 | 117.6 | (98.0-140.0) |  | Female | 13 | 13.4 | 97.3 | (51.7-166.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 11.9 | 92.1 | (45.9-164.9) |
| Female | 5 | 3.3 | 151.9 | (49.0-354.6) |  | Female | 7 | 5.7 | 123.3 | (49.4-254.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 25 | 28.5 | 87.8 | (56.8-129.6) |  |  |  |  |  |  |
| Female | 23 | 28.1 | 81.9 | (51.9-122.9) |  | Female | 6 | 9.1 | 65.6 | (23.9-142.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 6.8 | 132.6 | (60.5-251.7) |  | Male | 10 | 9.6 | 104.5 | (50.0-192.2) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 13 | 9.9 | 131.9 | (70.2-225.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 95 | 80.5 | 118.0 | (95.5-144.3) |
| Female | 1 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 14.2 | 84.6 | (43.7-147.8) |  | Male | 6 | 6.5 | 92.9 | (33.9-202.3) |
| Female | 6 | 8.5 | 70.4 | (25.7-153.3) |  | Female | 1 | 3.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 3.9 | nc | (nc-nc) |  | Male | 4 | 2.2 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 10.6 | 104.0 | (51.9-186.1) |  | Male | 7 | 5.8 | 120.6 | (48.3-248.4) |
| Female | 8 | 7.6 | 105.9 | (45.6-208.6) |  | Female | 14 | 17.7 | 79.2 | (43.3-132.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 8.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 3.2 | nc | (nc-nc) |  | Female | 20 | 24.2 | 82.5 | (50.4-127.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 28 | 48.2 | 58.1 | (38.6-83.9) |  | Male | 339 | 336.8 | 100.7 | (90.2-112.0) |
| Female | 39 | 51.5 | 75.8 | (53.9-103.6) |  | Female | 364 | 356.9 | 102.0 | (91.8-113.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

177

# Marion

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 7.5 | 66.6 | (21.5-155.4) |  | Male | 10 | 4.5 | 222.1 | (106.3-408.5) |
| Female | 4 | 2.8 | nc | (nc-nc) |  | Female | 2 | 3.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 1.3 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 11 | 4.1 | 269.8 | (134.5-482.7) |
| Female | 34 | 27.1 | 125.5 | (86.9-175.4) |  | Female | 3 | 3.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 3.4 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 3 | 1.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 7.7 | 117.4 | (53.6-222.8) |  |  |  |  |  |  |
| Female | 11 | 8.0 | 137.9 | (68.7-246.7) |  | Female | 0 | 2.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 0 | 2.7 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 2.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 14 | 24.9 | 56.3 | (30.7-94.4) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 4.0 | nc | (nc-nc) |  | Male | 0 | 1.8 | nc | (nc-nc) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 2.8 | 281.2 | (121.1-554.0) |  | Male | 3 | 1.6 | nc | (nc-nc) |
| Female | 4 | 2.1 | nc | (nc-nc) |  | Female | 5 | 4.1 | 122.3 | (39.4-285.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 7 | 6.2 | 112.9 | (45.2-232.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 13.4 | 52.1 | (20.9-107.3) |  | Male | 84 | 95.2 | 88.3 | (70.4-109.3) |
| Female | 18 | 13.8 | 130.3 | (77.2-205.9) |  | Female | 107 | 94.7 | 113.0 | (92.6-136.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

178

# Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 34 | 39.5 | 86.0 | (59.6-120.2) |  | Male | 25 | 26.3 | 95.2 | (61.6-140.5) |
| Female | 11 | 13.4 | 81.8 | (40.8-146.4) |  | Female | 14 | 19.9 | 70.4 | (38.5-118.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 8.2 | 73.2 | (26.7-159.3) |  | Male | 7 | 8.3 | 84.5 | (33.8-174.1) |
| Female | 10 | 6.3 | 157.6 | (75.5-289.9) |  | Female | 6 | 6.2 | 96.8 | (35.4-210.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 18 | 23.4 | 76.9 | (45.6-121.5) |
| Female | 144 | 158.9 | 90.6 | (76.4-106.7) |  | Female | 23 | 19.4 | 118.6 | (75.1-177.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 20 | 19.6 | 101.9 | (62.2-157.4) |
| Female | 6 | 5.7 | 105.1 | (38.4-228.9) |  | Female | 19 | 8.2 | 232.2 | (139.7-362.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 43 | 44.2 | 97.2 | (70.3-130.9) |  |  |  |  |  |  |
| Female | 50 | 39.8 | 125.7 | (93.3-165.7) |  | Female | 15 | 13.5 | 111.1 | (62.2-183.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 12 | 10.3 | 116.6 | (60.2-203.7) |  | Male | 13 | 14.3 | 91.1 | (48.5-155.9) |
| Female | 6 | 2.6 | 227.7 | (83.2-495.6) |  | Female | 15 | 13.5 | 110.9 | (62.0-182.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 7 | 3.4 | 207.3 | (83.1-427.2) |  | Male | 107 | 122.6 | 87.3 | (71.5-105.4) |
| Female | 3 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 22 | 23.0 | 95.6 | (59.9-144.7) |  | Male | 5 | 9.7 | 51.3 | (16.5-119.7) |
| Female | 10 | 12.5 | 80.1 | (38.4-147.3) |  | Female | 5 | 5.4 | 93.1 | (30.0-217.2) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 7 | 6.0 | 115.8 | (46.4-238.6) |  | Male | 3 | 6.5 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 14 | 16.6 | 84.2 | (46.0-141.2) |  | Male | 11 | 11.1 | 99.1 | (49.4-177.4) |
| Female | 14 | 11.3 | 123.6 | (67.5-207.4) |  | Female | 44 | 31.7 | 139.0 | (101.0-186.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 13 | 14.2 | 91.2 | (48.5-156.0) |  |  |  |  |  |  |
| Female | 8 | 4.5 | 177.0 | (76.2-348.8) |  | Female | 33 | 35.1 | 94.1 | (64.8-132.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 52 | 70.8 | 73.5 | (54.9-96.4) |  | Male | 451 | 521.9 | 86.4 | (78.6-94.8) |
| Female | 71 | 71.8 | 98.8 | (77.2-124.7) |  | Female | 551 | 525.2 | 104.9 | (96.3-114.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

179

# Marshfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 27.4 | 69.3 | (41.7-108.2) |  | Male | 31 | 17.9 | 172.8 | (117.4-245.2) |
| Female | 10 | 9.0 | 110.8 | (53.0-203.8) |  | Female | 28 | 13.5 | 206.8 | (137.4-298.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 10 | 5.5 | 180.2 | (86.3-331.4) |  | Male | 13 | 5.8 | 225.1 | (119.7-384.9) |
| Female | 5 | 4.4 | 113.7 | (36.6-265.3) |  | Female | 1 | 4.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 13 | 16.1 | 80.8 | (43.0-138.1) |
| Female | 142 | 114.7 | 123.8 | (104.3-145.9) |  | Female | 12 | 13.4 | 89.4 | (46.2-156.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 12 | 14.4 | 83.3 | (43.0-145.4) |
| Female | 6 | 3.8 | 159.4 | (58.2-347.0) |  | Female | 4 | 5.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 21 | 30.7 | 68.4 | (42.3-104.6) |  |  |  |  |  |  |
| Female | 26 | 26.4 | 98.5 | (64.4-144.4) |  | Female | 10 | 9.7 | 103.3 | (49.4-189.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 7.5 | 106.4 | (45.8-209.7) |  | Male | 12 | 10.2 | 118.1 | (61.0-206.4) |
| Female | 0 | 1.9 | nc | (nc-nc) |  | Female | 12 | 9.1 | 132.0 | (68.1-230.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 112 | 97.0 | 115.4 | (95.0-138.9) |
| Female | 3 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 20 | 16.5 | 121.2 | (74.0-187.2) |  | Male | 3 | 6.8 | nc | (nc-nc) |
| Female | 6 | 8.8 | 68.6 | (25.0-149.2) |  | Female | 3 | 3.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 4.4 | nc | (nc-nc) |  | Male | 4 | 3.4 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 15 | 11.4 | 131.8 | (73.7-217.3) |  | Male | 9 | 7.3 | 123.0 | (56.1-233.5) |
| Female | 6 | 7.4 | 80.6 | (29.4-175.4) |  | Female | 19 | 21.0 | 90.6 | (54.5-141.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 13 | 10.4 | 125.2 | (66.6-214.2) |  |  |  |  |  |  |
| Female | 1 | 3.2 | nc | (nc-nc) |  | Female | 21 | 26.7 | 78.7 | (48.7-120.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 46 | 50.0 | 92.0 | (67.3-122.7) |  | Male | 390 | 374.1 | 104.2 | (94.2-115.1) |
| Female | 65 | 50.0 | 130.0 | (100.3-165.7) |  | Female | 407 | 366.7 | 111.0 | (100.5-122.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

180

# Mashpee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 30 | 23.0 | 130.3 | (87.9-186.1) |  | Male | 14 | 13.3 | 104.9 | (57.3-176.1) |
| Female | 7 | 9.0 | 77.7 | (31.1-160.1) |  | Female | 18 | 10.2 | 176.7 | (104.7-279.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.6 | nc | (nc-nc) |  | Male | 5 | 4.4 | 112.6 | (36.3-262.8) |
| Female | 1 | 3.3 | nc | (nc-nc) |  | Female | 2 | 3.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 15 | 11.9 | 125.9 | (70.4-207.6) |
| Female | 88 | 86.6 | 101.6 | (81.5-125.2) |  | Female | 15 | 11.6 | 128.9 | (72.1-212.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 15 | 9.2 | 162.3 | (90.8-267.7) |
| Female | 1 | 2.3 | nc | (nc-nc) |  | Female | 5 | 4.8 | 104.3 | (33.6-243.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 19 | 22.7 | 83.8 | (50.4-130.8) |  |  |  |  |  |  |
| Female | 21 | 24.3 | 86.3 | (53.4-131.9) |  | Female | 5 | 7.6 | 66.1 | (21.3-154.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 5.6 | 89.7 | (28.9-209.3) |  | Male | 10 | 7.8 | 128.5 | (61.5-236.3) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 9 | 9.0 | 100.5 | (45.8-190.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 65 | 66.1 | 98.3 | (75.9-125.4) |
| Female | 2 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 11.2 | 98.5 | (49.1-176.2) |  | Male | 3 | 5.3 | nc | (nc-nc) |
| Female | 8 | 7.3 | 109.0 | (46.9-214.8) |  | Female | 2 | 3.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 3.2 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 3 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 8.5 | 106.2 | (48.5-201.6) |  | Male | 3 | 4.4 | nc | (nc-nc) |
| Female | 10 | 6.5 | 154.1 | (73.8-283.3) |  | Female | 10 | 12.3 | 81.0 | (38.8-149.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 7.0 | 85.3 | (31.2-185.8) |  |  |  |  |  |  |
| Female | 0 | 2.8 | nc | (nc-nc) |  | Female | 12 | 20.0 | 60.1 | (31.0-104.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 39 | 40.6 | 96.0 | (68.3-131.3) |  | Male | 278 | 273.9 | 101.5 | (89.9-114.2) |
| Female | 48 | 48.5 | 99.0 | (73.0-131.3) |  | Female | 287 | 302.3 | 94.9 | (84.3-106.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

181

# Mattapoisett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 8.0 | 149.3 | (77.0-260.8) |  | Male | 7 | 5.1 | 138.5 | (55.5-285.4) |
| Female | 4 | 2.7 | nc | (nc-nc) |  | Female | 4 | 3.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 1 | 4.5 | nc | (nc-nc) |
| Female | 38 | 31.4 | 120.9 | (85.6-166.0) |  | Female | 5 | 3.8 | 131.1 | (42.2-305.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 3.9 | 337.5 | (179.5-577.1) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 8.3 | 144.6 | (74.6-252.6) |  |  |  |  |  |  |
| Female | 4 | 7.5 | nc | (nc-nc) |  | Female | 5 | 2.7 | 187.2 | (60.3-436.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 4 | 2.9 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 3 | 2.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 42 | 27.5 | 152.9 | (110.2-206.7) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 4.6 | nc | (nc-nc) |  | Male | 3 | 1.9 | nc | (nc-nc) |
| Female | 0 | 2.5 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 3.1 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 4 | 2.1 | nc | (nc-nc) |  | Female | 4 | 5.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 0.9 | nc | (nc-nc) |  | Female | 12 | 7.4 | 162.3 | (83.7-283.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 18 | 15.1 | 119.1 | (70.5-188.2) |  | Male | 139 | 105.6 | 131.7 | (110.7-155.5) |
| Female | 10 | 14.8 | 67.3 | (32.2-123.9) |  | Female | 106 | 102.6 | 103.3 | (84.6-125.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

182

# Maynard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 12.3 | 97.6 | (50.4-170.5) |  | Male | 6 | 7.9 | 75.9 | (27.7-165.2) |
| Female | 2 | 3.6 | nc | (nc-nc) |  | Female | 6 | 5.5 | 109.1 | (39.8-237.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 0 | 2.6 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 4 | 7.1 | nc | (nc-nc) |
| Female | 45 | 44.0 | 102.3 | (74.6-136.9) |  | Female | 3 | 5.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 6.0 | 83.8 | (27.0-195.6) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 4 | 2.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 19 | 13.4 | 142.1 | (85.5-221.9) |  |  |  |  |  |  |
| Female | 16 | 10.7 | 149.1 | (85.2-242.1) |  | Female | 1 | 3.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 3.2 | nc | (nc-nc) |  | Male | 4 | 4.4 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 4 | 3.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 31 | 38.7 | 80.2 | (54.5-113.8) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 7.0 | nc | (nc-nc) |  | Male | 1 | 3.0 | nc | (nc-nc) |
| Female | 3 | 3.4 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 5.0 | nc | (nc-nc) |  | Male | 3 | 3.1 | nc | (nc-nc) |
| Female | 4 | 3.0 | nc | (nc-nc) |  | Female | 11 | 8.7 | 127.1 | (63.4-227.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 4.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 4 | 10.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 22.0 | 45.5 | (21.8-83.6) |  | Male | 119 | 160.0 | 74.4 | (61.6-89.0) |
| Female | 17 | 18.9 | 89.8 | (52.3-143.9) |  | Female | 139 | 143.6 | 96.8 | (81.4-114.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

183

# Medfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 13.4 | 67.3 | (30.7-127.8) |  | Male | 12 | 8.7 | 137.3 | (70.8-239.8) |
| Female | 4 | 3.5 | nc | (nc-nc) |  | Female | 8 | 5.8 | 138.7 | (59.7-273.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.7 | nc | (nc-nc) |  | Male | 3 | 2.8 | nc | (nc-nc) |
| Female | 3 | 1.9 | nc | (nc-nc) |  | Female | 3 | 1.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 4 | 7.9 | nc | (nc-nc) |
| Female | 40 | 48.7 | 82.1 | (58.7-111.9) |  | Female | 5 | 5.4 | 93.1 | (30.0-217.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 6.7 | 133.4 | (60.9-253.3) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 14 | 14.9 | 93.9 | (51.3-157.6) |  |  |  |  |  |  |
| Female | 9 | 11.1 | 80.9 | (36.9-153.6) |  | Female | 3 | 4.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  | Male | 4 | 4.9 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 3.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 53 | 43.1 | 122.8 | (92.0-160.7) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 7.8 | 77.2 | (28.2-168.0) |  | Male | 1 | 3.3 | nc | (nc-nc) |
| Female | 2 | 3.6 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 2.1 | nc | (nc-nc) |  | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 5.5 | nc | (nc-nc) |  | Male | 4 | 3.5 | nc | (nc-nc) |
| Female | 6 | 3.1 | 194.1 | (70.9-422.5) |  | Female | 6 | 9.5 | 63.1 | (23.1-137.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 4.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 8 | 10.8 | 74.1 | (31.9-146.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 11 | 23.9 | 46.1 | (23.0-82.5) |  | Male | 149 | 176.9 | 84.2 | (71.2-98.9) |
| Female | 11 | 18.9 | 58.0 | (28.9-103.9) |  | Female | 119 | 151.5 | 78.5 | (65.1-94.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

184

# Medford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 56 | 55.3 | 101.3 | (76.5-131.6) |  | Male | 20 | 35.2 | 56.8 | (34.7-87.8) |
| Female | 19 | 22.2 | 85.7 | (51.6-133.9) |  | Female | 18 | 31.3 | 57.6 | (34.1-91.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 14 | 10.9 | 128.5 | (70.2-215.6) |  | Male | 11 | 11.0 | 99.6 | (49.6-178.1) |
| Female | 11 | 9.8 | 112.6 | (56.1-201.4) |  | Female | 11 | 10.0 | 110.0 | (54.9-196.9) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  | Male | 29 | 31.6 | 91.7 | (61.4-131.6) |
| Female | 228 | 236.6 | 96.3 | (84.2-109.7) |  | Female | 27 | 31.1 | 86.9 | (57.3-126.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 28 | 24.8 | 112.7 | (74.9-162.9) |
| Female | 8 | 8.5 | 94.6 | (40.7-186.5) |  | Female | 14 | 12.9 | 108.8 | (59.4-182.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 70 | 59.4 | 117.8 | (91.8-148.8) |  |  |  |  |  |  |
| Female | 75 | 64.5 | 116.3 | (91.5-145.8) |  | Female | 23 | 20.8 | 110.5 | (70.1-165.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 14 | 13.6 | 102.9 | (56.2-172.7) |  | Male | 16 | 19.3 | 82.8 | (47.3-134.5) |
| Female | 7 | 4.3 | 164.3 | (65.8-338.4) |  | Female | 16 | 22.5 | 71.2 | (40.7-115.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 6 | 5.0 | 119.2 | (43.5-259.5) |  | Male | 153 | 158.6 | 96.5 | (81.8-113.0) |
| Female | 5 | 4.5 | 111.3 | (35.9-259.8) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 27 | 29.6 | 91.2 | (60.1-132.7) |  | Male | 15 | 13.3 | 113.2 | (63.3-186.7) |
| Female | 25 | 19.1 | 130.9 | (84.7-193.2) |  | Female | 8 | 8.8 | 91.1 | (39.2-179.4) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 9 | 7.9 | 114.2 | (52.1-216.8) |  | Male | 12 | 9.9 | 120.8 | (62.4-211.0) |
| Female | 3 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 28 | 22.6 | 124.2 | (82.5-179.4) |  | Male | 11 | 14.3 | 76.8 | (38.3-137.5) |
| Female | 17 | 18.2 | 93.4 | (54.4-149.6) |  | Female | 41 | 47.5 | 86.2 | (61.9-117.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 25 | 18.1 | 137.7 | (89.1-203.4) |  |  |  |  |  |  |
| Female | 7 | 7.3 | 96.5 | (38.7-198.8) |  | Female | 54 | 52.8 | 102.2 | (76.8-133.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 114 | 96.3 | 118.4 | (97.7-142.2) |  | Male | 715 | 697.2 | 102.6 | (95.2-110.4) |
| Female | 134 | 114.2 | 117.4 | (98.3-139.0) |  | Female | 828 | 816.6 | 101.4 | (94.6-108.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

185

# Medway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 13 | 11.5 | 112.9 | (60.1-193.1) |  | Male | 9 | 7.9 | 113.5 | (51.8-215.5) |
| Female | 2 | 4.4 | nc | (nc-nc) |  | Female | 3 | 6.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.5 | nc | (nc-nc) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 11 | 7.2 | 152.9 | (76.2-273.7) |
| Female | 58 | 54.5 | 106.5 | (80.9-137.7) |  | Female | 9 | 6.6 | 137.0 | (62.5-260.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 6.5 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 2 | 2.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 13.7 | 124.2 | (72.3-198.9) |  |  |  |  |  |  |
| Female | 9 | 14.3 | 63.1 | (28.8-119.9) |  | Female | 5 | 4.6 | 107.5 | (34.7-251.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 3.3 | 152.8 | (49.2-356.5) |  | Male | 3 | 4.4 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 3 | 4.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 54 | 41.7 | 129.6 | (97.3-169.1) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 7.4 | 81.0 | (29.6-176.4) |  | Male | 1 | 2.9 | nc | (nc-nc) |
| Female | 1 | 4.1 | nc | (nc-nc) |  | Female | 0 | 1.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 5.0 | nc | (nc-nc) |  | Male | 4 | 3.5 | nc | (nc-nc) |
| Female | 5 | 3.9 | 128.7 | (41.5-300.3) |  | Female | 11 | 10.5 | 104.5 | (52.1-186.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 4.7 | 106.7 | (34.4-249.1) |  |  |  |  |  |  |
| Female | 2 | 1.5 | nc | (nc-nc) |  | Female | 12 | 11.8 | 101.5 | (52.4-177.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 21.0 | 90.5 | (54.5-141.4) |  | Male | 175 | 163.4 | 107.1 | (91.8-124.2) |
| Female | 21 | 22.6 | 93.0 | (57.5-142.1) |  | Female | 161 | 177.7 | 90.6 | (77.2-105.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

186

# Melrose

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 30.0 | 50.0 | (28.0-82.5) |  | Male | 16 | 19.1 | 83.6 | (47.8-135.8) |
| Female | 9 | 11.2 | 80.2 | (36.6-152.3) |  | Female | 22 | 15.6 | 141.5 | (88.6-214.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 5.8 | 86.2 | (27.8-201.1) |  | Male | 4 | 6.1 | nc | (nc-nc) |
| Female | 9 | 4.9 | 182.3 | (83.2-346.2) |  | Female | 3 | 5.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 23 | 17.2 | 133.6 | (84.7-200.5) |
| Female | 130 | 124.2 | 104.7 | (87.4-124.3) |  | Female | 19 | 15.8 | 120.4 | (72.4-188.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 14.1 | 78.0 | (38.9-139.6) |
| Female | 2 | 4.3 | nc | (nc-nc) |  | Female | 5 | 6.7 | 75.0 | (24.2-175.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 45 | 32.5 | 138.5 | (101.0-185.3) |  |  |  |  |  |  |
| Female | 34 | 33.1 | 102.7 | (71.1-143.6) |  | Female | 7 | 10.7 | 65.3 | (26.1-134.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 7.7 | 117.4 | (53.6-222.9) |  | Male | 16 | 10.6 | 150.5 | (86.0-244.4) |
| Female | 0 | 2.2 | nc | (nc-nc) |  | Female | 13 | 11.5 | 113.1 | (60.2-193.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 2.2 | nc | (nc-nc) |  | Male | 83 | 92.8 | 89.4 | (71.2-110.9) |
| Female | 2 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 16.8 | 77.2 | (41.1-132.1) |  | Male | 5 | 7.2 | 69.2 | (22.3-161.5) |
| Female | 8 | 9.9 | 81.1 | (34.9-159.7) |  | Female | 3 | 4.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 7 | 4.4 | 158.9 | (63.7-327.4) |  | Male | 3 | 4.3 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 19 | 12.2 | 155.5 | (93.6-242.9) |  | Male | 9 | 7.8 | 115.2 | (52.6-218.8) |
| Female | 10 | 9.2 | 109.1 | (52.2-200.7) |  | Female | 26 | 23.2 | 111.9 | (73.1-164.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 10.2 | 48.9 | (15.8-114.2) |  |  |  |  |  |  |
| Female | 5 | 3.7 | 135.6 | (43.7-316.5) |  | Female | 32 | 27.9 | 114.6 | (78.3-161.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 47 | 52.9 | 88.8 | (65.3-118.1) |  | Male | 371 | 386.5 | 96.0 | (86.5-106.3) |
| Female | 60 | 58.3 | 102.9 | (78.5-132.5) |  | Female | 437 | 419.3 | 104.2 | (94.7-114.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

187

# Mendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 6.1 | nc | (nc-nc) |  | Male | 3 | 4.1 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 2 | 2.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 4 | 3.7 | nc | (nc-nc) |
| Female | 17 | 24.2 | 70.2 | (40.9-112.4) |  | Female | 5 | 2.7 | 187.5 | (60.4-437.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 3.3 | 150.5 | (48.5-351.2) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 7.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 5 | 5.1 | 97.2 | (31.3-226.9) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 4 | 1.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 21 | 22.0 | 95.6 | (59.2-146.2) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 3.8 | nc | (nc-nc) |  | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 2.6 | 195.3 | (63.0-455.9) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 2 | 1.5 | nc | (nc-nc) |  | Female | 6 | 4.7 | 126.8 | (46.3-275.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 8 | 5.6 | 143.6 | (61.9-283.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 10.9 | 45.7 | (14.7-106.6) |  | Male | 62 | 84.7 | 73.2 | (56.1-93.9) |
| Female | 7 | 9.5 | 73.6 | (29.5-151.7) |  | Female | 75 | 74.8 | 100.3 | (78.9-125.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

188

# Merrimac

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 7.0 | 85.3 | (31.1-185.6) |  | Male | 4 | 4.6 | nc | (nc-nc) |
| Female | 4 | 2.4 | nc | (nc-nc) |  | Female | 3 | 3.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 3 | 4.1 | nc | (nc-nc) |
| Female | 22 | 30.9 | 71.1 | (44.6-107.7) |  | Female | 3 | 3.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 3.5 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 7.8 | 116.1 | (53.0-220.4) |  |  |  |  |  |  |
| Female | 5 | 7.5 | 67.1 | (21.6-156.6) |  | Female | 5 | 2.6 | 190.5 | (61.4-444.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 2 | 0.5 | nc | (nc-nc) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 23 | 23.7 | 97.0 | (61.4-145.5) |
| Female | 2 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 4.1 | nc | (nc-nc) |  | Male | 3 | 1.7 | nc | (nc-nc) |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 3 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 2.9 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 2 | 5.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 0.8 | nc | (nc-nc) |  | Female | 1 | 7.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 13 | 12.9 | 100.6 | (53.5-172.1) |  | Male | 90 | 94.1 | 95.6 | (76.9-117.5) |
| Female | 22 | 13.3 | 164.8 | (103.3-249.6) |  | Female | 92 | 99.0 | 92.9 | (74.9-113.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

189

# Methuen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 43 | 45.8 | 93.8 | (67.9-126.3) |  | Male | 21 | 30.5 | 68.9 | (42.6-105.3) |
| Female | 22 | 18.3 | 120.1 | (75.3-181.9) |  | Female | 24 | 25.6 | 93.9 | (60.2-139.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 12 | 9.8 | 123.0 | (63.5-214.8) |  | Male | 10 | 9.7 | 102.7 | (49.2-188.9) |
| Female | 11 | 8.2 | 134.1 | (66.8-239.9) |  | Female | 8 | 8.4 | 95.7 | (41.2-188.5) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 1.6 | nc | (nc-nc) |  | Male | 34 | 27.4 | 124.2 | (86.0-173.6) |
| Female | 184 | 206.6 | 89.1 | (76.7-102.9) |  | Female | 25 | 25.8 | 96.7 | (62.6-142.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 22 | 23.6 | 93.3 | (58.4-141.2) |
| Female | 9 | 7.0 | 128.1 | (58.5-243.2) |  | Female | 8 | 10.9 | 73.7 | (31.7-145.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 46 | 51.1 | 90.1 | (66.0-120.2) |  |  |  |  |  |  |
| Female | 54 | 53.5 | 100.9 | (75.8-131.6) |  | Female | 15 | 17.7 | 84.8 | (47.4-139.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 12.4 | 72.8 | (33.2-138.2) |  | Male | 14 | 16.9 | 82.8 | (45.2-138.9) |
| Female | 3 | 3.6 | nc | (nc-nc) |  | Female | 22 | 18.5 | 118.6 | (74.3-179.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 7 | 3.9 | 178.7 | (71.6-368.2) |  | Male | 149 | 154.7 | 96.3 | (81.5-113.1) |
| Female | 1 | 3.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 30 | 27.4 | 109.7 | (74.0-156.6) |  | Male | 17 | 11.4 | 149.6 | (87.1-239.5) |
| Female | 23 | 16.4 | 140.4 | (88.9-210.6) |  | Female | 3 | 7.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 10 | 7.3 | 136.7 | (65.4-251.3) |  | Male | 13 | 7.1 | 183.9 | (97.8-314.5) |
| Female | 5 | 2.3 | 219.1 | (70.6-511.2) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 27 | 19.5 | 138.4 | (91.2-201.4) |  | Male | 16 | 12.8 | 125.1 | (71.4-203.1) |
| Female | 18 | 14.9 | 120.5 | (71.4-190.4) |  | Female | 42 | 38.7 | 108.5 | (78.2-146.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 15 | 17.2 | 87.0 | (48.7-143.6) |  |  |  |  |  |  |
| Female | 6 | 6.0 | 99.8 | (36.4-217.2) |  | Female | 46 | 45.9 | 100.3 | (73.4-133.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 101 | 83.5 | 120.9 | (98.5-146.9) |  | Male | 639 | 622.3 | 102.7 | (94.9-111.0) |
| Female | 128 | 97.1 | 131.8 | (109.9-156.7) |  | Female | 721 | 691.2 | 104.3 | (96.8-112.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

190

# Middleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 32 | 24.9 | 128.4 | (87.8-181.2) |  | Male | 19 | 16.2 | 117.0 | (70.4-182.7) |
| Female | 12 | 8.8 | 136.7 | (70.5-238.7) |  | Female | 9 | 12.7 | 70.7 | (32.2-134.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 5.1 | 117.6 | (42.9-256.0) |  | Male | 5 | 5.3 | 95.2 | (30.7-222.1) |
| Female | 5 | 4.0 | 125.0 | (40.3-291.7) |  | Female | 6 | 4.1 | 147.2 | (53.8-320.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 12 | 14.7 | 81.7 | (42.2-142.8) |
| Female | 115 | 104.3 | 110.3 | (91.1-132.4) |  | Female | 8 | 12.5 | 63.8 | (27.5-125.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 12 | 12.7 | 94.4 | (48.7-165.0) |
| Female | 6 | 3.5 | 172.1 | (62.8-374.6) |  | Female | 8 | 5.3 | 149.7 | (64.5-295.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 33 | 27.8 | 118.8 | (81.8-166.9) |  |  |  |  |  |  |
| Female | 25 | 25.8 | 97.1 | (62.8-143.3) |  | Female | 11 | 8.9 | 124.3 | (62.0-222.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 6.7 | 118.7 | (51.1-233.9) |  | Male | 13 | 9.1 | 142.8 | (76.0-244.3) |
| Female | 3 | 1.7 | nc | (nc-nc) |  | Female | 11 | 8.9 | 123.8 | (61.7-221.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 90 | 86.5 | 104.0 | (83.6-127.8) |
| Female | 2 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 21 | 14.9 | 140.7 | (87.1-215.1) |  | Male | 6 | 6.1 | 98.2 | (35.8-213.7) |
| Female | 5 | 8.2 | 61.3 | (19.8-143.1) |  | Female | 0 | 3.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 3.9 | nc | (nc-nc) |  | Male | 5 | 3.4 | 148.3 | (47.8-346.2) |
| Female | 6 | 1.1 | 526.8 | (192.3-1146.6) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 10.4 | 115.4 | (59.6-201.6) |  | Male | 7 | 6.7 | 104.3 | (41.8-214.9) |
| Female | 13 | 7.2 | 181.6 | (96.6-310.6) |  | Female | 24 | 19.5 | 122.9 | (78.7-182.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 13 | 9.1 | 143.0 | (76.1-244.6) |  |  |  |  |  |  |
| Female | 7 | 2.9 | 238.9 | (95.7-492.3) |  | Female | 31 | 23.3 | 133.1 | (90.4-189.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 62 | 45.4 | 136.4 | (104.6-174.9) |  | Male | 384 | 337.6 | 113.7 | (102.6-125.7) |
| Female | 69 | 47.7 | 144.6 | (112.5-183.0) |  | Female | 407 | 341.8 | 119.1 | (107.8-131.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

191

# Middlefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 3.1 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 3.5 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 9 | 13.2 | 68.3 | (31.2-129.7) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 8 | 9.9 | 80.8 | (34.8-159.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

192

# Middleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 10.7 | 139.6 | (78.1-230.3) |  | Male | 9 | 7.2 | 124.7 | (56.9-236.8) |
| Female | 2 | 2.8 | nc | (nc-nc) |  | Female | 3 | 4.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.3 | nc | (nc-nc) |  | Male | 3 | 2.3 | nc | (nc-nc) |
| Female | 3 | 1.3 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 14 | 6.5 | 214.1 | (117.0-359.3) |
| Female | 43 | 33.2 | 129.6 | (93.8-174.6) |  | Female | 7 | 4.0 | 175.6 | (70.3-361.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 5.7 | 87.8 | (28.3-204.9) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 12.3 | 89.2 | (44.5-159.7) |  |  |  |  |  |  |
| Female | 11 | 8.1 | 136.3 | (68.0-244.0) |  | Female | 0 | 2.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  | Male | 3 | 4.0 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 1 | 2.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 35 | 37.5 | 93.3 | (65.0-129.8) |
| Female | 2 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 6.6 | nc | (nc-nc) |  | Male | 4 | 2.7 | nc | (nc-nc) |
| Female | 5 | 2.6 | 191.2 | (61.6-446.2) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  | Male | 3 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 4.5 | 110.0 | (35.5-256.7) |  | Male | 2 | 3.2 | nc | (nc-nc) |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 8 | 6.0 | 132.9 | (57.2-261.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 4.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 12 | 7.5 | 159.9 | (82.5-279.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 21 | 19.1 | 110.0 | (68.0-168.1) |  | Male | 156 | 148.1 | 105.4 | (89.5-123.3) |
| Female | 16 | 15.4 | 103.6 | (59.2-168.2) |  | Female | 128 | 108.7 | 117.8 | (98.3-140.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

193

# Milford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 45 | 26.3 | 170.9 | (124.6-228.7) |  | Male | 14 | 17.4 | 80.3 | (43.9-134.7) |
| Female | 14 | 9.7 | 144.0 | (78.6-241.6) |  | Female | 14 | 14.3 | 97.6 | (53.3-163.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 5.5 | nc | (nc-nc) |  | Male | 4 | 5.5 | nc | (nc-nc) |
| Female | 5 | 4.6 | 108.2 | (34.9-252.6) |  | Female | 8 | 4.5 | 177.6 | (76.5-349.9) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 23 | 15.7 | 146.4 | (92.8-219.6) |
| Female | 110 | 113.7 | 96.8 | (79.5-116.6) |  | Female | 21 | 14.1 | 149.4 | (92.5-228.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 14 | 13.1 | 106.7 | (58.3-179.0) |
| Female | 4 | 4.0 | nc | (nc-nc) |  | Female | 5 | 5.9 | 84.1 | (27.1-196.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 31 | 29.7 | 104.3 | (70.8-148.0) |  |  |  |  |  |  |
| Female | 30 | 29.2 | 102.7 | (69.3-146.6) |  | Female | 9 | 9.8 | 92.3 | (42.1-175.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 10 | 6.8 | 146.0 | (69.9-268.6) |  | Male | 8 | 9.5 | 83.8 | (36.1-165.2) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 7 | 9.9 | 70.4 | (28.2-145.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 2.3 | 218.4 | (70.4-509.7) |  | Male | 105 | 82.4 | 127.4 | (104.2-154.3) |
| Female | 1 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 17 | 15.4 | 110.5 | (64.3-176.9) |  | Male | 14 | 6.5 | 215.3 | (117.6-361.3) |
| Female | 13 | 8.9 | 146.7 | (78.1-250.9) |  | Female | 1 | 4.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 4.0 | nc | (nc-nc) |  | Male | 4 | 4.4 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 11.2 | 98.5 | (49.1-176.3) |  | Male | 3 | 7.5 | nc | (nc-nc) |
| Female | 11 | 8.3 | 133.0 | (66.3-238.0) |  | Female | 23 | 22.4 | 102.8 | (65.1-154.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 9.4 | 63.7 | (23.2-138.6) |  |  |  |  |  |  |
| Female | 3 | 3.2 | nc | (nc-nc) |  | Female | 30 | 25.1 | 119.6 | (80.7-170.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 47 | 46.5 | 101.1 | (74.3-134.4) |  | Male | 396 | 348.7 | 113.6 | (102.7-125.3) |
| Female | 60 | 50.9 | 117.9 | (90.0-151.8) |  | Female | 404 | 377.7 | 107.0 | (96.8-117.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

194

# Millbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 14.3 | 132.8 | (79.9-207.5) |  | Male | 6 | 9.5 | 63.3 | (23.1-137.8) |
| Female | 2 | 4.9 | nc | (nc-nc) |  | Female | 9 | 7.2 | 125.3 | (57.2-238.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 2.9 | nc | (nc-nc) |  | Male | 6 | 3.0 | 196.8 | (71.9-428.3) |
| Female | 1 | 2.3 | nc | (nc-nc) |  | Female | 7 | 2.3 | 305.8 | (122.5-630.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 17 | 8.6 | 198.8 | (115.7-318.3) |
| Female | 63 | 58.7 | 107.3 | (82.5-137.3) |  | Female | 3 | 7.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 7.4 | 135.2 | (64.7-248.6) |
| Female | 3 | 2.0 | nc | (nc-nc) |  | Female | 3 | 3.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 15.9 | 62.9 | (30.1-115.6) |  |  |  |  |  |  |
| Female | 15 | 14.7 | 101.8 | (56.9-167.9) |  | Female | 5 | 5.0 | 100.6 | (32.4-234.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 3.9 | 154.0 | (56.2-335.3) |  | Male | 6 | 5.3 | 113.4 | (41.4-246.7) |
| Female | 4 | 1.0 | nc | (nc-nc) |  | Female | 10 | 5.0 | 199.8 | (95.7-367.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 54 | 49.5 | 109.1 | (81.9-142.3) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 8.7 | 160.7 | (87.8-269.7) |  | Male | 2 | 3.5 | nc | (nc-nc) |
| Female | 6 | 4.6 | 130.5 | (47.7-284.1) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 2.3 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 5.9 | 134.8 | (58.0-265.7) |  | Male | 10 | 4.0 | 248.6 | (119.0-457.2) |
| Female | 6 | 4.1 | 145.9 | (53.3-317.6) |  | Female | 13 | 11.2 | 116.3 | (61.9-198.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 5.1 | 117.0 | (42.7-254.7) |  |  |  |  |  |  |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 9 | 13.2 | 68.4 | (31.2-129.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 46 | 26.2 | 175.5 | (128.5-234.1) |  | Male | 247 | 194.4 | 127.1 | (111.7-144.0) |
| Female | 31 | 26.2 | 118.1 | (80.3-167.7) |  | Female | 208 | 192.7 | 108.0 | (93.8-123.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

195

# Millis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 6.3 | 174.4 | (86.9-312.1) |  | Male | 3 | 4.7 | nc | (nc-nc) |
| Female | 3 | 2.8 | nc | (nc-nc) |  | Female | 4 | 4.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 4 | 4.2 | nc | (nc-nc) |
| Female | 32 | 35.0 | 91.4 | (62.5-129.0) |  | Female | 5 | 4.1 | 121.9 | (39.3-284.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 4.1 | 147.7 | (53.9-321.6) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 8.2 | 122.3 | (58.5-224.9) |  |  |  |  |  |  |
| Female | 10 | 8.5 | 117.8 | (56.4-216.6) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 3 | 2.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 31 | 24.5 | 126.6 | (86.0-179.7) |
| Female | 3 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 4.5 | 132.1 | (48.3-287.6) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 4 | 2.7 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 2.9 | nc | (nc-nc) |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 5 | 2.4 | 211.4 | (68.1-493.4) |  | Female | 11 | 6.7 | 164.1 | (81.8-293.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 7 | 7.8 | 89.8 | (36.0-185.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 9 | 12.1 | 74.6 | (34.1-141.7) |  | Male | 106 | 96.1 | 110.2 | (90.3-133.3) |
| Female | 15 | 15.4 | 97.1 | (54.3-160.2) |  | Female | 117 | 113.4 | 103.2 | (85.4-123.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

196

# Millville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 2.1 | 242.6 | (78.2-566.2) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 13 | 12.8 | 101.9 | (54.2-174.3) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 3.1 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 12 | 7.9 | 151.0 | (77.9-263.7) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 2 | 0.6 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 0 | 2.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 2 | 2.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 3.9 | 179.3 | (71.8-369.5) |  | Male | 44 | 32.2 | 136.6 | (99.2-183.3) |
| Female | 11 | 5.3 | 207.2 | (103.3-370.7) |  | Female | 37 | 41.0 | 90.3 | (63.5-124.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

197

# Milton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 27.2 | 62.5 | (36.4-100.1) |  | Male | 34 | 17.1 | 199.2 | (137.9-278.4) |
| Female | 9 | 10.7 | 84.1 | (38.4-159.7) |  | Female | 24 | 14.2 | 168.8 | (108.1-251.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 5.4 | nc | (nc-nc) |  | Male | 5 | 5.5 | 90.9 | (29.3-212.0) |
| Female | 5 | 4.7 | 105.5 | (34.0-246.2) |  | Female | 11 | 4.8 | 228.6 | (114.0-409.1) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 17 | 15.5 | 109.6 | (63.8-175.6) |
| Female | 141 | 114.4 | 123.3 | (103.7-145.4) |  | Female | 11 | 14.8 | 74.3 | (37.0-132.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 12.7 | 63.0 | (27.1-124.1) |
| Female | 4 | 3.8 | nc | (nc-nc) |  | Female | 4 | 6.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 24 | 29.3 | 81.9 | (52.5-121.9) |  |  |  |  |  |  |
| Female | 28 | 31.5 | 89.0 | (59.1-128.7) |  | Female | 18 | 9.9 | 181.5 | (107.5-286.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 6.9 | 130.3 | (59.4-247.3) |  | Male | 9 | 9.7 | 93.2 | (42.5-176.9) |
| Female | 4 | 2.1 | nc | (nc-nc) |  | Female | 11 | 11.0 | 100.4 | (50.1-179.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  | Male | 100 | 83.8 | 119.3 | (97.0-145.1) |
| Female | 5 | 1.9 | 269.0 | (86.7-627.7) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 14.9 | 80.3 | (41.4-140.3) |  | Male | 5 | 6.5 | 76.7 | (24.7-179.1) |
| Female | 12 | 9.2 | 130.7 | (67.5-228.4) |  | Female | 5 | 4.3 | 116.8 | (37.6-272.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 4.0 | nc | (nc-nc) |  | Male | 2 | 3.7 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 13 | 11.2 | 115.8 | (61.6-198.0) |  | Male | 5 | 6.8 | 73.8 | (23.8-172.2) |
| Female | 8 | 8.7 | 91.9 | (39.6-181.1) |  | Female | 34 | 20.9 | 162.5 | (112.5-227.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 9.3 | 53.8 | (17.3-125.6) |  |  |  |  |  |  |
| Female | 1 | 3.4 | nc | (nc-nc) |  | Female | 33 | 25.2 | 131.1 | (90.2-184.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 34 | 47.8 | 71.2 | (49.3-99.5) |  | Male | 338 | 348.9 | 96.9 | (86.8-107.8) |
| Female | 48 | 55.2 | 87.0 | (64.2-115.4) |  | Female | 445 | 390.6 | 113.9 | (103.6-125.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

198

# Monroe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 2.6 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

199

# Monson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 11.3 | 88.4 | (42.3-162.6) |  | Male | 5 | 7.1 | 69.9 | (22.5-163.2) |
| Female | 1 | 3.2 | nc | (nc-nc) |  | Female | 1 | 4.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 0 | 2.4 | nc | (nc-nc) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 3 | 6.4 | nc | (nc-nc) |
| Female | 45 | 41.5 | 108.4 | (79.0-145.0) |  | Female | 7 | 4.8 | 144.7 | (58.0-298.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 5.6 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 4 | 2.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 12.4 | 72.6 | (33.1-137.8) |  |  |  |  |  |  |
| Female | 5 | 9.5 | 52.7 | (17.0-122.9) |  | Female | 0 | 3.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 3.0 | nc | (nc-nc) |  | Male | 4 | 4.1 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 2 | 3.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 28 | 37.6 | 74.5 | (49.5-107.6) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 6.4 | 77.8 | (25.1-181.6) |  | Male | 1 | 2.7 | nc | (nc-nc) |
| Female | 0 | 3.2 | nc | (nc-nc) |  | Female | 2 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 4.4 | nc | (nc-nc) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 3 | 7.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 4.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 7 | 9.8 | 71.2 | (28.5-146.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 15 | 20.2 | 74.4 | (41.6-122.7) |  | Male | 106 | 148.1 | 71.6 | (58.6-86.6) |
| Female | 14 | 17.9 | 78.2 | (42.7-131.2) |  | Female | 106 | 132.1 | 80.3 | (65.7-97.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

200

# Montague

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 10.1 | 79.6 | (34.3-156.8) |  | Male | 8 | 6.2 | 129.5 | (55.8-255.2) |
| Female | 6 | 3.9 | 152.5 | (55.7-332.0) |  | Female | 1 | 5.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 1.8 | 276.7 | (89.2-645.8) |  | Male | 3 | 2.0 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 0 | 1.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 5 | 5.5 | 90.3 | (29.1-210.6) |
| Female | 35 | 42.2 | 83.0 | (57.8-115.4) |  | Female | 3 | 5.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 4.5 | nc | (nc-nc) |
| Female | 3 | 1.4 | nc | (nc-nc) |  | Female | 3 | 2.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 10.5 | 85.4 | (39.0-162.1) |  |  |  |  |  |  |
| Female | 12 | 11.6 | 103.7 | (53.5-181.1) |  | Female | 8 | 3.7 | 217.6 | (93.7-428.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 2.5 | nc | (nc-nc) |  | Male | 0 | 3.5 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 2 | 4.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 21 | 30.7 | 68.4 | (42.3-104.6) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 5.3 | nc | (nc-nc) |  | Male | 4 | 2.4 | nc | (nc-nc) |
| Female | 4 | 3.4 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 1.4 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 4.0 | 176.6 | (70.8-363.9) |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 5 | 3.1 | 160.2 | (51.6-373.8) |  | Female | 3 | 7.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 3.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 12 | 9.8 | 122.9 | (63.4-214.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 18 | 17.5 | 102.8 | (60.9-162.5) |  | Male | 119 | 126.1 | 94.4 | (78.2-112.9) |
| Female | 17 | 20.1 | 84.5 | (49.2-135.2) |  | Female | 125 | 143.5 | 87.1 | (72.5-103.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

201

# Monterey

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 3 | 1.0 | nc | (nc-nc) |
| Female | 2 | 0.4 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 5 | 4.5 | 111.2 | (35.9-259.6) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 5.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.1 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 3.0 | nc | (nc-nc) |  | Male | 11 | 20.7 | 53.2 | (26.5-95.2) |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 11 | 15.4 | 71.6 | (35.7-128.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

202

# Montgomery

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 3 | 4.6 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 8 | 4.1 | 194.7 | (83.8-383.7) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 2.1 | nc | (nc-nc) |  | Male | 17 | 15.8 | 107.6 | (62.6-172.2) |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 7 | 14.8 | 47.4 | (19.0-97.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

203

# Mount Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 2 | 3.4 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 3 | 4.8 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

204

# Nahant

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 4.6 | 109.2 | (35.2-254.7) |  | Male | 8 | 2.8 | 290.0 | (124.9-571.4) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 7 | 2.6 | 270.7 | (108.4-557.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 17 | 20.8 | 81.7 | (47.6-130.9) |  | Female | 2 | 2.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 2.1 | nc | (nc-nc) |
| Female | 2 | 0.6 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 4.8 | 105.0 | (33.8-245.0) |  |  |  |  |  |  |
| Female | 6 | 6.3 | 95.6 | (34.9-208.2) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 21 | 14.7 | 142.4 | (88.1-217.7) |
| Female | 2 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 1.8 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 2 | 3.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 5 | 4.8 | 105.2 | (33.9-245.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 8.0 | 125.0 | (59.8-229.8) |  | Male | 73 | 57.8 | 126.3 | (99.0-158.8) |
| Female | 6 | 10.8 | 55.6 | (20.3-121.1) |  | Female | 64 | 73.3 | 87.3 | (67.2-111.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

205

# Nantucket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 10.9 | 82.7 | (37.7-157.0) |  | Male | 18 | 7.3 | 246.9 | (146.3-390.3) |
| Female | 3 | 3.3 | nc | (nc-nc) |  | Female | 19 | 5.0 | 380.9 | (229.2-594.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 8 | 2.3 | 341.4 | (147.0-672.8) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 3 | 6.5 | nc | (nc-nc) |
| Female | 52 | 40.3 | 128.9 | (96.3-169.1) |  | Female | 4 | 4.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 5.5 | 182.3 | (87.3-335.3) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 5 | 2.1 | 243.5 | (78.5-568.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 12.0 | 58.3 | (23.3-120.1) |  |  |  |  |  |  |
| Female | 13 | 9.6 | 134.7 | (71.7-230.4) |  | Female | 3 | 3.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  | Male | 3 | 3.9 | nc | (nc-nc) |
| Female | 4 | 0.7 | nc | (nc-nc) |  | Female | 4 | 3.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 1.0 | nc | (nc-nc) |  | Male | 33 | 35.6 | 92.6 | (63.7-130.0) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 6.5 | nc | (nc-nc) |  | Male | 0 | 2.7 | nc | (nc-nc) |
| Female | 0 | 3.2 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 4.6 | 153.3 | (61.4-315.8) |  | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 4 | 2.8 | nc | (nc-nc) |  | Female | 13 | 8.1 | 161.4 | (85.8-276.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 4.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 11 | 9.1 | 121.5 | (60.6-217.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 15 | 19.8 | 75.8 | (42.4-125.0) |  | Male | 141 | 146.4 | 96.3 | (81.1-113.6) |
| Female | 20 | 18.1 | 110.7 | (67.6-171.0) |  | Female | 168 | 131.9 | 127.4 | (108.9-148.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

206

# Natick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 29 | 34.4 | 84.2 | (56.4-120.9) |  | Male | 17 | 22.6 | 75.3 | (43.9-120.6) |
| Female | 11 | 13.4 | 82.2 | (41.0-147.0) |  | Female | 18 | 18.9 | 95.1 | (56.3-150.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 7.1 | 99.1 | (39.7-204.3) |  | Male | 3 | 7.2 | nc | (nc-nc) |
| Female | 8 | 6.1 | 131.6 | (56.7-259.3) |  | Female | 5 | 6.2 | 80.9 | (26.1-188.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 1.2 | nc | (nc-nc) |  | Male | 16 | 20.3 | 78.9 | (45.1-128.2) |
| Female | 135 | 157.0 | 86.0 | (72.1-101.8) |  | Female | 13 | 19.0 | 68.4 | (36.4-117.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 18 | 17.2 | 104.9 | (62.1-165.8) |
| Female | 2 | 5.3 | nc | (nc-nc) |  | Female | 12 | 8.1 | 148.3 | (76.5-259.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 38 | 38.1 | 99.8 | (70.6-136.9) |  |  |  |  |  |  |
| Female | 44 | 39.5 | 111.4 | (80.9-149.5) |  | Female | 19 | 13.3 | 143.0 | (86.1-223.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 10 | 9.1 | 110.2 | (52.7-202.6) |  | Male | 10 | 12.5 | 80.0 | (38.3-147.0) |
| Female | 4 | 2.6 | nc | (nc-nc) |  | Female | 10 | 13.5 | 74.1 | (35.5-136.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.8 | nc | (nc-nc) |  | Male | 110 | 110.9 | 99.2 | (81.5-119.5) |
| Female | 1 | 2.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 20 | 20.1 | 99.7 | (60.9-154.0) |  | Male | 9 | 8.4 | 106.6 | (48.7-202.4) |
| Female | 12 | 12.3 | 97.3 | (50.2-169.9) |  | Female | 1 | 5.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 5.3 | 113.5 | (41.4-247.0) |  | Male | 7 | 5.1 | 136.5 | (54.7-281.2) |
| Female | 4 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 13 | 14.4 | 90.1 | (47.9-154.1) |  | Male | 13 | 9.4 | 138.4 | (73.6-236.6) |
| Female | 5 | 11.0 | 45.6 | (14.7-106.5) |  | Female | 28 | 28.8 | 97.1 | (64.5-140.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 12.4 | 56.5 | (22.7-116.5) |  |  |  |  |  |  |
| Female | 3 | 4.5 | nc | (nc-nc) |  | Female | 40 | 34.8 | 114.9 | (82.1-156.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 47 | 61.6 | 76.3 | (56.0-101.4) |  | Male | 415 | 456.6 | 90.9 | (82.4-100.1) |
| Female | 55 | 72.1 | 76.3 | (57.4-99.3) |  | Female | 462 | 516.0 | 89.5 | (81.5-98.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

207

# Needham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 35 | 36.8 | 95.0 | (66.2-132.2) |  | Male | 30 | 22.1 | 135.6 | (91.5-193.6) |
| Female | 16 | 13.1 | 122.5 | (70.0-199.0) |  | Female | 18 | 17.0 | 106.0 | (62.8-167.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 9 | 6.5 | 138.9 | (63.4-263.8) |  | Male | 8 | 7.1 | 113.0 | (48.7-222.7) |
| Female | 11 | 5.5 | 199.5 | (99.4-357.0) |  | Female | 4 | 5.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 27 | 20.0 | 135.1 | (89.0-196.5) |
| Female | 170 | 137.6 | 123.5 | (105.7-143.6) |  | Female | 24 | 17.9 | 134.2 | (85.9-199.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 16.0 | 68.7 | (34.2-122.9) |
| Female | 2 | 4.4 | nc | (nc-nc) |  | Female | 5 | 7.6 | 66.1 | (21.3-154.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 29 | 38.7 | 74.9 | (50.1-107.5) |  |  |  |  |  |  |
| Female | 41 | 39.0 | 105.1 | (75.4-142.6) |  | Female | 11 | 11.9 | 92.1 | (45.9-164.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 8.9 | 78.5 | (31.5-161.8) |  | Male | 9 | 12.8 | 70.2 | (32.0-133.2) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 16 | 13.7 | 116.8 | (66.7-189.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 115 | 106.0 | 108.5 | (89.6-130.2) |
| Female | 2 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 17 | 18.8 | 90.5 | (52.7-144.9) |  | Male | 5 | 8.6 | 57.9 | (18.7-135.1) |
| Female | 11 | 10.9 | 100.6 | (50.1-180.0) |  | Female | 3 | 5.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 5.0 | nc | (nc-nc) |  | Male | 4 | 3.5 | nc | (nc-nc) |
| Female | 0 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 14.5 | 68.8 | (32.9-126.5) |  | Male | 8 | 8.0 | 100.1 | (43.1-197.2) |
| Female | 14 | 10.5 | 132.7 | (72.5-222.7) |  | Female | 31 | 23.6 | 131.2 | (89.1-186.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 11.9 | 42.0 | (13.5-97.9) |  |  |  |  |  |  |
| Female | 1 | 4.2 | nc | (nc-nc) |  | Female | 31 | 30.5 | 101.7 | (69.1-144.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 41 | 62.5 | 65.6 | (47.1-89.1) |  | Male | 404 | 449.5 | 89.9 | (81.3-99.1) |
| Female | 39 | 65.3 | 59.7 | (42.5-81.7) |  | Female | 486 | 470.1 | 103.4 | (94.4-113.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

208

# New Ashford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 3 | 4.0 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 4 | 3.9 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

209

# New Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 102 | 94.8 | 107.5 | (87.7-130.6) |  | Male | 27 | 60.1 | 44.9 | (29.6-65.4) |
| Female | 31 | 38.4 | 80.7 | (54.8-114.5) |  | Female | 23 | 51.3 | 44.8 | (28.4-67.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 16 | 18.8 | 85.3 | (48.7-138.6) |  | Male | 19 | 19.1 | 99.6 | (59.9-155.5) |
| Female | 13 | 16.7 | 77.9 | (41.4-133.1) |  | Female | 15 | 17.2 | 87.4 | (48.9-144.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 3.3 | nc | (nc-nc) |  | Male | 44 | 54.1 | 81.3 | (59.0-109.1) |
| Female | 345 | 396.4 | 87.0 | (78.1-96.7) |  | Female | 49 | 52.7 | 93.0 | (68.8-123.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 55 | 43.9 | 125.3 | (94.4-163.1) |
| Female | 16 | 13.5 | 118.6 | (67.8-192.7) |  | Female | 27 | 21.9 | 123.4 | (81.3-179.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 121 | 101.9 | 118.7 | (98.5-141.9) |  |  |  |  |  |  |
| Female | 105 | 112.8 | 93.1 | (76.1-112.7) |  | Female | 28 | 34.9 | 80.3 | (53.4-116.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 28 | 23.9 | 116.9 | (77.7-169.0) |  | Male | 36 | 33.6 | 107.3 | (75.1-148.5) |
| Female | 9 | 7.3 | 122.8 | (56.0-233.1) |  | Female | 53 | 39.5 | 134.2 | (100.5-175.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 8 | 7.7 | 104.4 | (44.9-205.7) |  | Male | 307 | 288.8 | 106.3 | (94.7-118.9) |
| Female | 5 | 6.8 | 73.8 | (23.8-172.3) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 56 | 52.0 | 107.8 | (81.4-139.9) |  | Male | 39 | 22.8 | 171.4 | (121.9-234.3) |
| Female | 35 | 32.2 | 108.8 | (75.7-151.3) |  | Female | 21 | 15.4 | 136.5 | (84.4-208.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 27 | 13.8 | 195.1 | (128.5-283.8) |  | Male | 10 | 14.2 | 70.3 | (33.7-129.3) |
| Female | 8 | 4.5 | 179.1 | (77.1-353.0) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 33 | 39.0 | 84.6 | (58.2-118.8) |  | Male | 21 | 23.9 | 88.0 | (54.4-134.5) |
| Female | 20 | 31.6 | 63.4 | (38.7-97.9) |  | Female | 77 | 74.8 | 102.9 | (81.2-128.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 65 | 32.2 | 202.0 | (155.9-257.5) |  |  |  |  |  |  |
| Female | 13 | 12.2 | 106.3 | (56.6-181.8) |  | Female | 83 | 87.2 | 95.2 | (75.8-118.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 254 | 166.9 | 152.2 | (134.0-172.1) |  | Male | 1370 | 1214.1 | 112.8 | (106.9-119.0) |
| Female | 198 | 194.5 | 101.8 | (88.1-117.0) |  | Female | 1297 | 1379.1 | 94.0 | (89.0-99.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

210

# New Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 2 | 4.6 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 1.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 6 | 4.2 | 143.9 | (52.6-313.3) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 19 | 15.7 | 120.9 | (72.8-188.8) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 13 | 15.2 | 85.4 | (45.4-146.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

211

# New Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 2.8 | nc | (nc-nc) |  | Male | 3 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 2 | 1.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 10 | 9.0 | 111.4 | (53.3-204.9) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 2.3 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 9.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 5.0 | nc | (nc-nc) |  | Male | 19 | 35.3 | 53.8 | (32.4-84.0) |
| Female | 3 | 4.4 | nc | (nc-nc) |  | Female | 24 | 29.6 | 81.2 | (52.0-120.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

212

# New Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 3 | 5.2 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 1.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 5 | 5.1 | 98.4 | (31.7-229.6) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 3 | 1.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 2.5 | nc | (nc-nc) |  | Male | 15 | 18.6 | 80.7 | (45.2-133.2) |
| Female | 1 | 2.3 | nc | (nc-nc) |  | Female | 16 | 16.8 | 95.0 | (54.3-154.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

213